Wutah dodolan YoY sajrone 12 wulan kepungkur: Compass Therapeutics (CMPX)

Compass Therapeutics focuses on developing anti-tumor antibodies, while a lack of profitability leads to rising costs as testing expands. Development is conducted through laboratory partnerships and the acquisition of patents, with production and distribution outsourced. The current year-over-year revenue growth rate on a TTM basis clearly demonstrates revenue dynamics, where -99.80 serves as the base parameter value.

For Compass Therapeutics (CMPX), whose valuation depends on the outcome of cancer immunotherapy clinical trials, the absence of commercial products makes revenue a secondary factor. This indicator measures the percentage change in total revenue over 12 months relative to the same period last year, allowing for an assessment of business scaling rates via the current TTM revenue growth and the timely detection of stagnation.